CD273 (B7-DC) Monoclonal Antibody (122), PE, eBioscience™, Invitrogen™

Description

Description: The 122 monoclonal antibody reacts with mouse B7-DC, also known as PD-L2. B7-DC, a recently identified member of the B7 family, has a predicted molecular weight of approximately 25 kDa and belongs to the Ig superfamily. The mouse B7-DC has a short cytoplasmic tail (4aa). B7-DC is primarily expressed by subpopulations of dendritic cells and monocytes/macrophages in the mouse. Although B7-DC has structural and sequence similarities to the B7 family, it does not bind CD28/CTLA-4, rather it is a ligand for PD-1. The interactions between PD-1 and B7-DC/PD-L2 have been reported to be involved in costimulation or suppression of T cell proliferation depending on state of cellular activation. 122 has been demonstrated to block binding of TY25 (Cat. No.14-5986), another mAb specific for mouse B7-DC. Applications Reported: 122 has been reported for use in flow cytometric analysis. Applications Tested: The 122 antibody has been tested by flow cytometric analysis of mouse dendritic cells or mouse B7-DC transfected cells. This can be used at less than or equal to 0.125 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 μm post-manufacturing filtered. Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by co gnate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PDL-2 can act to stimulate an immunogenic response through and alternative receptor from PD-1. At least three isoforms of PDL-2 are known to exist; this antibody is specific to the largest isoform. PDL-2 antibody has no cross-reactivity to PDL-2.